Patients at risk for postoperative hypocalcemia need more vigilant postoperative monitoring. Low preoperative serum calcium levels increase the likelihood of hypocalcemia after parathyroidectomy (PTx) ...

The US Food and Drug Administration (FDA) has added a boxed warning to the label of the osteoporosis drug denosumab (Prolia) about increased risk for severe hypocalcemia in patients with advanced ...

Researchers are attempting to identify treatment strategies that would allow for shorter therapy dur In a large, single-center study, severe hypocalcemia developed in 1 in 4 patients who underwent ...

Please provide your email address to receive an email when new articles are posted on . Hypocalcemia risk increased with worsening CKD stages, particularly for patients on dialysis. Emergently treated ...

The use of the osteoporosis drug denosumab (Prolia) to prevent fractures associated with advanced chronic kidney disease (CKD) in patients on kidney dialysis significantly increases the risk for ...

The FDA said it's looking into the risk of severe hypocalcemia among patients on dialysis receiving denosumab (Prolia), citing the potential for severe outcomes, including hospitalization and death.

According to a long-term safety study and a separate FDA internal study, Prolia had an increased risk of hypocalcemia in patients with advanced kidney disease on dialysis. Patients with advanced ...

Progressive locally advanced or metastatic radioiodine-refractory differentiated thyroid cancer (RAI-R DTC) patients treated with donafenib: A real world study. This is an ASCO Meeting Abstract from ...

Panel A shows the clinical characteristics and treatments for all six unrelated patients with autosomal dominant hypocalcemia type 1 (ADH1) who received continuous subcutaneous parathyroid hormone ...

Real-World Outcomes in Patients With Metastatic Renal Cell Carcinoma Treated With First-Line Nivolumab Plus Ipilimumab in the United States Denosumab is widely used in the treatment of bone metastases ...